---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-007177"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T16:10:47.309279+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics raises ~$1.8M via registered direct offering and private placement

## Summary
- Sold 800,877 shares (or common stock equivalents) at $2.285 per share, gross proceeds ~$1.8M.
- Issued warrants to purchase up to 800,877 shares at $2.16/share, exercisable immediately, 5.5-year term.
- Placement agent H.C. Wainwright will receive 7% cash fee and warrants for 56,061 shares at $2.8563/share.
- Closing expected on or about May 26, 2023, subject to customary conditions.
- Proceeds to be used for general corporate purposes including R&D, clinical trials, and working capital.

## SEC filing metadata
- accession: 0001654954-23-007177
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495423007177/0001654954-23-007177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495423007177/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-007177
- JSON: https://secwatch.observer/filing/0001654954-23-007177.json
- Plain text: https://secwatch.observer/filing/0001654954-23-007177.txt

## Key facts
- Material Agreements
  Dermata Therapeutics, Inc. entered into Purchase Agreement with the investors named on the signature pages thereto valued at approximately $1.8 million (effective 2023-05-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the investors named on the signature pages thereto
  - Value: approximately $1.8 million
  - Effective: 2023-05-23
  source text: On May 23, 2023, Dermata Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with the investors named on the signature pages thereto (collectively, the “ Purchasers ”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 458,555 shares (the “ Shares ”) of common stock, par value $0.0001, of the Company (“ Common Stock ”) at a purchase price of $2.285 per Share and accompanying Warrant (as defined below), and (ii) 342,322 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 342,322 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) at a purchase price of $2.2849 per Pre-Funded Warrant and accompanying Warrant, for aggregate gross proceeds to the Company of approximately $1.8 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495423007177/0001654954-23-007177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.